Published in Semin Liver Dis on February 01, 2003
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol (2004) 1.24
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int (2008) 1.01
Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis (2010) 0.93
Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria. BMC Res Notes (2012) 0.88
Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. J Korean Med Sci (2010) 0.87
Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment. World J Gastroenterol (2007) 0.86
Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol (2008) 0.81
Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine (2006) 0.80
Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol (2006) 0.80
Hepatitis B virus infection: An insight into infection outcomes and recent treatment options. Virusdisease (2015) 0.80
Current antiviral therapy for chronic hepatitis B. J Korean Med Sci (2004) 0.79
Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients. Dig Dis Sci (2012) 0.78
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol (2005) 2.69
Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol Lett (2004) 1.95
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol (2003) 1.75
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol (2008) 1.62
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58
Is there a place for cardiovascular magnetic resonance imaging in the evaluation of cardiovascular involvement in rheumatic diseases? Semin Arthritis Rheum (2011) 1.44
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis (2006) 1.40
Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm (2009) 1.26
The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol (2006) 1.23
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol (2011) 1.15
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med (2006) 1.12
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology (2012) 1.03
Influence of sleep disturbance on quality of life of patients with epilepsy. Seizure (2008) 1.00
Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int (2005) 0.99
Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol (2008) 0.98
Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann Neurol (2005) 0.96
Association of demographic, clinical and treatment variables with quality of life of patients with epilepsy in Greece. Qual Life Res (2008) 0.95
Effect of CAG repeat length on psychiatric disorders in Huntington's disease. J Psychiatr Res (2007) 0.94
Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. Eur J Gastroenterol Hepatol (2002) 0.94
Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol (2006) 0.94
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol (2009) 0.93
Nonepisodic memory deficits in amnestic MCI. Cogn Behav Neurol (2007) 0.92
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int (2010) 0.91
Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol (2007) 0.91
Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol (2009) 0.90
Structural and functional impairment of the retina and optic nerve in Alzheimer's disease. Curr Alzheimer Res (2012) 0.90
Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol (2010) 0.87
Current progress in the treatment of chronic hepatitis C. World J Gastroenterol (2012) 0.87
Morphometric study of the human muscle spindle. Anal Quant Cytol Histol (2005) 0.87
Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol (2009) 0.86
Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford) (2013) 0.86
Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology (2002) 0.86
Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int (2011) 0.85
Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 0.85
Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. Ann Hepatol (2005) 0.84
NRAMP1 polymorphism and viral factors in Sardinian multiple sclerosis patients. Can J Neurol Sci (2008) 0.84
Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review. J Clin Rheumatol (2005) 0.84
The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol (2013) 0.84
Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int (2013) 0.83
Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother (2003) 0.83
Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol (2012) 0.82
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther (2004) 0.82
Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington's disease. Neuro Endocrinol Lett (2007) 0.81
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. J Hepatol (2003) 0.81
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr Opin Investig Drugs (2010) 0.81
Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation. J Heart Lung Transplant (2007) 0.81
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis (2012) 0.81
Precore mutant chronic hepatitis B - approach to management. MedGenMed (2003) 0.81
Reduced expression of metabotropic glutamate receptor 2mRNA in T cells of ALS patients. Ann Neurol (2005) 0.81
Higher levels of extroverted hostility detected in gene carriers at risk for Huntington's disease. Biol Psychiatry (2007) 0.80
Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile. Clin Vaccine Immunol (2013) 0.80
Modulation of voltage-gated potassium channels in human T lymphocytes by extracellular glutamate. Mol Pharmacol (2005) 0.80
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? J Gastroenterol Hepatol (2006) 0.79
Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J Cardiovasc Med (Hagerstown) (2016) 0.79
Increased plasma homocysteine levels in patients with multiple sclerosis and depression. Ann Gen Psychiatry (2008) 0.79
Aberrant modulation of a delayed rectifier potassium channel by glutamate in Alzheimer's disease. Neurobiol Dis (2009) 0.79
Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Liver Transpl (2007) 0.79
Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. Antivir Ther (2011) 0.79
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J Hepatol (2003) 0.78
Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2015) 0.78
Plasma homovanillic acid and prolactin in Huntington's disease. Neurochem Res (2008) 0.78
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int (2015) 0.78
Prevalence of interatrial block in patients with Friedreich's ataxia. Int J Cardiol (2010) 0.78
Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum. J Rheumatol (2008) 0.78
Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin. Ann Pharmacother (2005) 0.78
The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. Eur J Gastroenterol Hepatol (2010) 0.78
Adipokines and insulin resistance in chronic hepatitis C. Hepatology (2007) 0.77
The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol (2013) 0.77
Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. Dig Dis Sci (2007) 0.77
Toward understanding cognitive impairment in patients with myotonic dystrophy type 1. Arch Clin Neuropsychol (2010) 0.77
Naftidrofuryl-induced liver injury. Am J Gastroenterol (2003) 0.77
Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord (2007) 0.77
Clinicopathological features and natural history of acute sporadic non-(A-E) hepatitis. J Gastroenterol Hepatol (2008) 0.77
HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? Liver Int (2014) 0.77
Neuroendocrine evidence of normal hypothalamus-pituitary dopaminergic function in Huntington's disease. Neuro Endocrinol Lett (2010) 0.77
ECG changes mimicking myocardial infarction. Am J Med (2010) 0.77
Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol (2013) 0.77
Telbivudine in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol (2008) 0.77
Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology (2010) 0.76
Emerging treatments in chronic hepatitis B. Expert Opin Emerg Drugs (2004) 0.76
Myelodysplastic syndrome presenting as acquired ichthyosis. Eur J Intern Med (2006) 0.76
Same or opposite? Association of head-movement weakness with limb paresis in stroke. Neurologist (2011) 0.76
Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice. Hepatology (2010) 0.76
Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med (2004) 0.76
Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scand J Gastroenterol (2007) 0.76
Morphological and morphometrical study of human muscle spindles in Werdnig-Hoffmann disease (infantile spinal muscular atrophy type I). Acta Histochem (2006) 0.76
Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther (2011) 0.76
Morphologic and morphometrical study of the muscle spindle in muscular dystrophy. Anal Quant Cytol Histol (2007) 0.76
Cochlear function in facioscapulohumeral muscular dystrophy. Otol Neurotol (2007) 0.75
Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection. Clin Vaccine Immunol (2007) 0.75